Industry payments in Neurology Subspecialties: 2014-2018

Objective: To explore payments from the industry to the physicians in various neurology subspecialties. Background: Financial transactions between the industry and physicians introduce potential conflicts of interest, which may translate to patient care. Open Payments is a national disclosure program to promote transparency by the public disclosure of financial relationships between the pharmaceutical and medical device industries and physicians. We explored payments from the industry to physicians in various neurology subspecialties. Design/Methods: Open Payments Program (OPP) data (https://openpaymentsdata.cms.gov) on industry-to-physician payments for the years 2014–2018 were extracted for general neurology, neuromuscular, neurophysiology, and vascular neurology. The data were then analyzed to explore trends in payments for various subspecialties and to identify the possible factors underlying these trends. Results: Overall, industry-to-physician payments for neurology subspecialties increased by 16% from 2014 to 2018. The introduction of newer drugs in a subspecialty was likely the driving factor for higher industry payments. Nearly half of the total industry-to-physician payments were for the subspecialty of multiple sclerosis (MS)/Neuroimmunology; this coincided with Aubagio and Copaxone being the top two medications associated with the highest industry payments in 2014, Aubagio, and Lemtrada in 2018. A significant increase in spending percentages for headache, neuromuscular disorders, and movement disorders was observed while a relative decrease in the payments for Neuroimmunology and epilepsy was identified; these trends coincide with the introduction of new drugs such as Aimovig, Neuplazid, Nusinersen, and Austedo for headache, neuromuscular and movement disorders. Conclusions: From 2014 to 2018, the total industry-to-physician payments for neurology subspecialties increased while the distribution of industry-to-physician payments for various neurology subspecialties showed notable changes. The introduction of newer medications in a subspecialty coincided with higher industry payments. Identification of these trends and potential motives of the industry spending is critical to address any potential physician bias in prescribing medications. Disclosure: Dr. Battini has nothing to disclose. Dr. Veerapaneni has nothing to disclose. Dr. Arulprakash has nothing to disclose. Dr. Bahekar has nothing to disclose. Dr. Sheng has nothing to disclose. Dr. Lopez-Castellanos has nothing to disclose. Dr. Dandu has nothing to disclose. Suman Siddamreddy has nothing to disclose. Dr. Veerapaneni has nothing to disclose. Dr. Onteddu has nothing to disclose. Dr. Nalleballe has nothing to disclose.